BIOCARDIA INC (BCDA) Fundamental Analysis & Valuation

NASDAQ:BCDA • US09060U6064

1.18 USD
-0.03 (-2.07%)
At close: Mar 6, 2026
1.1774 USD
0 (-0.22%)
After Hours: 3/6/2026, 8:02:04 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Forecast Earnings Financials Ownership News

This BCDA fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

1

We assign a fundamental rating of 1 out of 10 to BCDA. BCDA was compared to 519 industry peers in the Biotechnology industry. BCDA may be in some trouble as it scores bad on both profitability and health. While showing a medium growth rate, BCDA is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

0

1. BCDA Profitability Analysis

1.1 Basic Checks

  • BCDA had negative earnings in the past year.
  • In the past year BCDA has reported a negative cash flow from operations.
  • BCDA had negative earnings in each of the past 5 years.
  • BCDA had a negative operating cash flow in each of the past 5 years.
BCDA Yearly Net Income VS EBIT VS OCF VS FCFBCDA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 -5M -10M -15M

1.2 Ratios

  • Looking at the Return On Assets, with a value of -421.11%, BCDA is doing worse than 93.46% of the companies in the same industry.
Industry RankSector Rank
ROA -421.11%
ROE N/A
ROIC N/A
ROA(3y)-240.8%
ROA(5y)-173.35%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
BCDA Yearly ROA, ROE, ROICBCDA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500 -500 1K

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for BCDA so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
BCDA Yearly Profit, Operating, Gross MarginsBCDA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -2K -4K -6K -8K -10K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

1

2. BCDA Health Analysis

2.1 Basic Checks

  • BCDA does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for BCDA has been increased compared to 1 year ago.
  • The number of shares outstanding for BCDA has been reduced compared to 5 years ago.
  • BCDA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
BCDA Yearly Shares OutstandingBCDA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M
BCDA Yearly Total Debt VS Total AssetsBCDA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M

2.2 Solvency

  • BCDA has an Altman-Z score of -123.97. This is a bad value and indicates that BCDA is not financially healthy and even has some risk of bankruptcy.
  • Looking at the Altman-Z score, with a value of -123.97, BCDA is doing worse than 94.23% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -123.97
ROIC/WACCN/A
WACC8.79%
BCDA Yearly LT Debt VS Equity VS FCFBCDA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10M -10M 20M

2.3 Liquidity

  • BCDA has a Current Ratio of 0.33. This is a bad value and indicates that BCDA is not financially healthy enough and could expect problems in meeting its short term obligations.
  • Looking at the Current ratio, with a value of 0.33, BCDA is doing worse than 91.92% of the companies in the same industry.
  • BCDA has a Quick Ratio of 0.33. This is a bad value and indicates that BCDA is not financially healthy enough and could expect problems in meeting its short term obligations.
  • BCDA has a Quick ratio of 0.33. This is amonst the worse of the industry: BCDA underperforms 91.54% of its industry peers.
Industry RankSector Rank
Current Ratio 0.33
Quick Ratio 0.33
BCDA Yearly Current Assets VS Current LiabilitesBCDA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. BCDA Growth Analysis

3.1 Past

  • BCDA shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 17.91%, which is quite good.
  • The Revenue for BCDA has decreased by -64.67% in the past year. This is quite bad
  • BCDA shows a decrease in Revenue. Measured over the last years, the Revenue has been decreasing by -5.41% yearly.
EPS 1Y (TTM)17.91%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%60.66%
Revenue 1Y (TTM)-64.67%
Revenue growth 3Y47.05%
Revenue growth 5Y-5.41%
Sales Q2Q%N/A

3.2 Future

  • Based on estimates for the next years, BCDA will show a quite strong growth in Earnings Per Share. The EPS will grow by 14.32% on average per year.
  • Based on estimates for the next years, BCDA will show a very strong growth in Revenue. The Revenue will grow by 70.15% on average per year.
EPS Next Y61.55%
EPS Next 2Y36.3%
EPS Next 3Y23.83%
EPS Next 5Y14.33%
Revenue Next Year-84.28%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y70.15%

3.3 Evolution

  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
BCDA Yearly Revenue VS EstimatesBCDA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2028 2M 4M 6M 8M
BCDA Yearly EPS VS EstimatesBCDA Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 -5 -10 -15 -20 -25

More info and screens

Find the best growth stocksShow best growing peers

1

4. BCDA Valuation Analysis

4.1 Price/Earnings Ratio

  • BCDA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for BCDA. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
BCDA Price Earnings VS Forward Price EarningsBCDA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
BCDA Per share dataBCDA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share -0.5 -1

4.3 Compensation for Growth

  • A more expensive valuation may be justified as BCDA's earnings are expected to grow with 23.83% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y36.3%
EPS Next 3Y23.83%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. BCDA Dividend Analysis

5.1 Amount

  • No dividends for BCDA!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

BCDA Fundamentals: All Metrics, Ratios and Statistics

BIOCARDIA INC

NASDAQ:BCDA (3/6/2026, 8:02:04 PM)

After market: 1.1774 0 (-0.22%)

1.18

-0.03 (-2.07%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-12
Earnings (Next)04-01
Inst Owners6.12%
Inst Owner Change52.09%
Ins Owners18.47%
Ins Owner Change6.08%
Market Cap12.52M
Revenue(TTM)477.00K
Net Income(TTM)-8.80M
Analysts82.5
Price Target25.5 (2061.02%)
Short Float %3.04%
Short Ratio2.93
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-13.37%
Min EPS beat(2)-48.32%
Max EPS beat(2)21.57%
EPS beat(4)3
Avg EPS beat(4)20.95%
Min EPS beat(4)-48.32%
Max EPS beat(4)60.78%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)61.29%
PT rev (3m)61.29%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)5.35%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)-100%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-1.48
EYN/A
EPS(NY)-1.17
Fwd EYN/A
FCF(TTM)-0.8
FCFYN/A
OCF(TTM)-0.8
OCFYN/A
SpS0
BVpS-0.18
TBVpS-0.18
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -421.11%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-240.8%
ROA(5y)-173.35%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 15.91%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.33
Quick Ratio 0.33
Altman-Z -123.97
F-Score2
WACC8.79%
ROIC/WACCN/A
Cap/Depr(3y)36.91%
Cap/Depr(5y)70.72%
Cap/Sales(3y)6.02%
Cap/Sales(5y)9.96%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)17.91%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%60.66%
EPS Next Y61.55%
EPS Next 2Y36.3%
EPS Next 3Y23.83%
EPS Next 5Y14.33%
Revenue 1Y (TTM)-64.67%
Revenue growth 3Y47.05%
Revenue growth 5Y-5.41%
Sales Q2Q%N/A
Revenue Next Year-84.28%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y70.15%
EBIT growth 1Y-2.89%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year0.9%
EBIT Next 3Y-11.84%
EBIT Next 5Y-0.64%
FCF growth 1Y21.23%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y21.07%
OCF growth 3YN/A
OCF growth 5YN/A

BIOCARDIA INC / BCDA FAQ

Can you provide the ChartMill fundamental rating for BIOCARDIA INC?

ChartMill assigns a fundamental rating of 1 / 10 to BCDA.


Can you provide the valuation status for BIOCARDIA INC?

ChartMill assigns a valuation rating of 1 / 10 to BIOCARDIA INC (BCDA). This can be considered as Overvalued.


Can you provide the profitability details for BIOCARDIA INC?

BIOCARDIA INC (BCDA) has a profitability rating of 0 / 10.


What is the expected EPS growth for BIOCARDIA INC (BCDA) stock?

The Earnings per Share (EPS) of BIOCARDIA INC (BCDA) is expected to grow by 61.55% in the next year.